Clinical Trials · global
Follow-up Extended to 84 Weeks: Pasatru Provides Evidence of Sustained Control in a Rare Ossification Disorder
In patients with FOP, abnormal bone gradually forms in soft tissues. The OPTIMA extension trial showed no new ossification lesions detected in the Pasatru treatment groups from weeks 56 to 84, but the higher dose was associated with more skin and soft tissue infections. Long-term benefits still need to be weighed alongside the risks.
For patients with fibrodysplasia ossificans progressiva (FOP), each additional site of abnormal bone formation may further restrict movement. Whether treatment can continue to suppress new lesions is therefore a question that affects daily life. On October 12, Regeneron announced 84-week results from the Phase 3 OPTIMA trial of Pasatru: from weeks 56 to 84, no new heterotopic ossification lesions were detected in adults receiving the drug, while 9 were detected in the placebo group.
FOP is an extremely rare genetic disease in which abnormal bone gradually invades muscles, ligaments, and other connective tissues, affecting walking, eating, and even breathing. Pasatru (garetosmab-grts) is a fully human monoclonal antibody that blocks signaling by Activin A, a protein involved in heterotopic ossification in FOP. According to the company’s announcement, the drug recently received approval from the U.S. Food and Drug Administration to reduce new ossification lesions and clinician-assessed disease flare-ups in adult patients.
The data were presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting. OPTIMA enrolled 63 adults, who were randomized to receive intravenous infusions every four weeks in three groups: 10 mg/kg, 3 mg/kg, and placebo. Of these, 58 completed the double-blind extension phase through at least week 84. Participants continued their originally assigned treatment, allowing the study to track differences between groups over a longer period.
Reporting by RTTNews also confirmed that imaging examinations from weeks 56 to 84 found no new ossification lesions in the treatment groups. During the same period, the number of physician-assessed flare-ups was 1 in the 10 mg/kg group, 14 in the 3 mg/kg group, and 17 in the placebo group. These figures are total numbers of flare-up events and cannot be directly interpreted as the proportion of patients who experienced flare-ups. The difference between the lower-dose group and the placebo group was also much smaller than that between the higher-dose group and placebo.
Beyond efficacy, infection risk differed by dose. The company’s announcement and a report by S&P Capital IQ published on MarketScreener indicated that the proportions of patients with skin and soft tissue infections were 33%, 53%, and 78% in the placebo, 3 mg/kg, and 10 mg/kg groups, respectively. All infections resolved after treatment, no patients discontinued the drug because of them, and no deaths were reported in the trial. However, this risk remains an important part of assessing long-term treatment.
Another imaging finding requires cautious interpretation: one lesion detected at week 56 in the 3 mg/kg group was no longer detectable at week 84. A change in a single lesion is insufficient to establish that the drug can broadly reverse existing ossification. These publicly released results primarily support a sustained effect in suppressing new lesions and do not provide complete data sufficient to determine whether walking ability, quality of life, or existing disability can improve.
The extension trial adds evidence of sustained efficacy in adults, but the sample size is limited, and the information currently available still comes primarily from company announcements and conference presentations. Regeneron plans to initiate the Phase 3 OPTIMA 2 trial in children and adolescents later in 2026. The adult results provide a foundation for research, while efficacy and safety in younger patients still need to be established through a dedicated trial.